KLK7 and psoriasis: Interestingly, two other approved therapeutics for psoriasis, broadalumab (anti-IL-17A) and etanercept (anti-TNF), also downregulate KLK-7 mirroring apremilast-induced effect, thus providing plausible explanations of converged therapeutic mechanism.